undervalued opportunity

1 articles
The Motley FoolThe Motley Fool··Jonathan Ponciano

Major Investor Stakes $45M Position in Flat-Performing Novanta Stock

ACK Asset Management buys $44.6M stake in underperforming Novanta, betting on cyclical recovery in medical device and industrial automation markets.
NOVTNOVTUMTRNGVAWMSinstitutional investmentmedical technology